- Home
- NXL vs EVAX Comparison
NXL vs EVAX Comparison
Compare NXL & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- EVAX
- Stock Information
- Founded
- NXL 2010
- EVAX 2008
- Country
- NXL United States
- EVAX Denmark
- Employees
- NXL N/A
- EVAX N/A
- Industry
- NXL Medical Specialities
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NXL Health Care
- EVAX Health Care
- Exchange
- NXL Nasdaq
- EVAX Nasdaq
- Market Cap
- NXL 10.0M
- EVAX 8.7M
- IPO Year
- NXL 2022
- EVAX 2021
- Fundamental
- Price
- NXL $3.23
- EVAX $0.88
- Analyst Decision
- NXL Hold
- EVAX Strong Buy
- Analyst Count
- NXL 1
- EVAX 2
- Target Price
- NXL N/A
- EVAX $11.00
- AVG Volume (30 Days)
- NXL 533.6K
- EVAX 77.4K
- Earning Date
- NXL 11-08-2024
- EVAX 10-31-2024
- Dividend Yield
- NXL N/A
- EVAX N/A
- EPS Growth
- NXL N/A
- EVAX N/A
- EPS
- NXL N/A
- EVAX N/A
- Revenue
- NXL $162,078.00
- EVAX $3,295,000.00
- Revenue This Year
- NXL $56.86
- EVAX $4,845.21
- Revenue Next Year
- NXL $167.44
- EVAX $30.30
- P/E Ratio
- NXL N/A
- EVAX N/A
- Revenue Growth
- NXL 26.00
- EVAX N/A
- 52 Week Low
- NXL $0.25
- EVAX $0.87
- 52 Week High
- NXL $4.49
- EVAX $13.61
- Technical
- Relative Strength Index (RSI)
- NXL 42.43
- EVAX 19.35
- Support Level
- NXL $3.25
- EVAX $1.08
- Resistance Level
- NXL $4.49
- EVAX $1.20
- Average True Range (ATR)
- NXL 0.35
- EVAX 0.18
- MACD
- NXL -0.17
- EVAX -0.01
- Stochastic Oscillator
- NXL 7.26
- EVAX 1.11
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.